Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome

British Journal of Haematology

Volumn 159, Issue 4, 2012, Pages 462-471

  Chatterjee, Ratna ^a   Shah, Farrukh T ^b   Davis, Bernard A ^b   Byers, Margaret ^c   Sooranna, Dev ^d   Bajoria, Rekha ^a   Pringle, Jean ^c   Porter, John B ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Thalassaemia major; Biochemical bone markers; Histomorphometry; Osteoporosis; Pamidronate

Indexed keywords

BIOCHEMICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; PAMIDRONIC ACID; PREMPACK C; PREMPAK; PROCOLLAGEN; PROCOLLAGEN TYPE 1 CARBOXY TERMINAL PROPEPTIDE; TESTOSTERONE; TESTOSTERONE CIPIONATE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ARTICLE; BONE DENSITOMETRY; BONE MARROW BIOPSY; BONE REMODELING; BONE TURNOVER; CASE CONTROL STUDY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; HYPOGONADISM; MALE; METABOLIC BONE DISEASE; MORPHOMETRICS; OSTEOID; OSTEOPENIA OSTEOPOROSIS SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPINE; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; TREATMENT DURATION;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; BONE REMODELING; BONE RESORPTION; CASE-CONTROL STUDIES; DENSITOMETRY; DIPHOSPHONATES; FEMALE; HUMANS; MALE; OSTEOPOROSIS; PROSPECTIVE STUDIES; SYNDROME; YOUNG ADULT;

EID: 84868200577     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12048     Document Type: Article

References (41)

1. Arisal, O., Deviren, A., Fenerci, E.Y., Hacihanefioglu, S., Ulutin, T., Erkmen, S. & Buyru, N. (2002) Polymorphism analysis in the COLIA1 gene of patients with thalassemia major and intermedia. Haematologia (Budap), 32, 475-482.
2. Bajoria, R. & Chatterjee, R. (2009) Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment. Hemoglobin, 33(Suppl. 1), S136-S138.
3. Bajoria, R., Sooranna, S.R. & Chatterjee, R. (2006) Type 1 collagen marker of bone turnover, IGF and leptin in dichorionic twins with discordant birth weight. Journal of Clinical Endocrinology and Metabolism, 91, 4696-4701.
4. Bone, H.G., Greenspan, S.L., McKeever, C., Bell, N., Davidson, M., Downs, R.W., Emkey, R., Meunier, P.J., Miller, S.S., Mulloy, A.L., Recker, R.R., Weiss, S.R., Heyden, N., Musliner, T., Suryawanshi, S., Yates, A.J. & Lombardi, A. (2000) Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. Journal of Clinical Endocrinology and Metabolism, 85, 720-726.
5. Bonnick, S.L. (2009) Bone Densitometry in Clinical Practice: Application and Interpretation, 3rd edn. pp. 297-321. Humana Press, New Jersey.
6. Carmina, E., Di Fede, G., Napoli, N., Renda, G., Vitale, G., Lo Pinto, C., Bruno, D., Malizia, R. & Rini, G.B. (2004) Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcified Tissue International, 74, 68-71.
7. Chan, Y.L., Pang, L.M., Chik, K.W., Cheng, J.C. & Li, C.K. (2002) Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatric Radiology, 32, 492-497.
8. Chatterjee, R. & Bajoria, R. (2010) Critical appraisal of growth retardation and pubertal disturbances in thalassemia. Annals of the New York Academy of Sciences, 1202, 100-114.
9. Chatterjee, R. & Katz, M. (2000) Reversible hypogonadotrophic hypogonadism in sexually infantile male thalassaemic patients with transfusional iron overload. Clinical Endocrinology (Oxford), 53, 33-42.
10. Chatterjee, R., Katz, M., Oatridge, A., Bydder, G.M. & Porter, J.B. (1998) Selective loss of anterior pituitary volume with severe pituitary-gonadal insufficiency in poorly compliant male thalassemic patients with pubertal arrest. Annals of the New York Academy of Sciences, 850, 479-482.
11. Chatterjee, R., Katz, M. & Bajoria, R. (2011) Use of HRT for correction of high turnover bone disease in hypogonadal beta thalassaemia major presenting with osteoporosis: comparison with idiopathic premature ovarian failure. Hemoglobin, 35, 653-658.
12. Chavassieux, P.M. & Delmas, P.D. (2006) Bone remodeling: biochemical markers or bone biopsy? Journal of Bone and Mineral Research, 21, 178-179.
13. Compston, J. (1998) Bone histomorphomtry. In: Osteopororsis (ed. by J.C. Steven & R. Lindsay), pp. 85-114. Chapman & Hall Medical Publications, New York.
14. Davis, B.A., O'Sullivan, C., Jarritt, P.H. & Porter, J.B. (2004) Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood, 104, 263-269.
15. Delmas, P.D. & Garnero, P. (1998) Biological markers of bone turnover in osteoporosis. In: Osteopororsis (ed. by J.C. Steven & R. Lindsay), pp. 117-136. Chapman & Hall Medical Publications, New York.
16. Desigan, S., Hall-Craggs, M.A., Ho, C.P., Eliahoo, J. & Porter, J.B. (2006) Degenerative disc disease as a cause of back pain in the thalassaemic population: a case-control study using MRI and plain radiographs. Skeletal Radiology, 35, 95-102.
17. Eren, E. & Yilmaz, N. (2005) Biochemical markers of bone turnover and bone mineral density in patients with β-thalassaemia major. International Journal of Clinical Practice, 59, 46-51.
18. Gluer, C.C. (2000) The use of bone densitometry in clinical practice. Baillière's Best Practice & Research. Clinical Endocrinology & Metabolism, 14, 195-211.
19. Green, J., Czanner, G., Reeves, G., Watson, J., Wise, L. & Beral, V. (2010) Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ, 341, c4444.
20. Harris, S.T., Eriksen, E.F., Davidson, M., Ettinger, M.P., Moffett, Jr, A.H., Baylink, D.J., Crusan, C.E. & Chines, A.A. (2001) Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. Journal of Clinical Endocrinology and Metabolism, 86, 1890-1897.
21. Hiratsuka, H., Katsuta, O., Toyota, N., Tsuchitani, M., Akiba, T., Marumo, F. & Umemura, T. (1997) Iron deposition at mineralization fronts and osteoid formation following chronic cadmium exposure in ovariectomized rats. Toxicology and Applied Pharmacology, 143, 348-356.
22. Lasco, A., Morabito, N., Gaudio, A., Crisafulli, A., Meo, A., Denuzzo, G. & Frisina, N. (2002) Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis. Journal of Endocrinological Investigation, 25, 338-344.
23. Lenart, B.A., Lorich, D.G. & Lane, J.M. (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. New England Journal of Medicine, 358, 1304-1306.
24. Mahachoklertwattana, P., Sirikulchayanonta, V., Chuansumrit, A., Karnsombat, P., Choubtum, L., Sriphrapradang, A., Domrongkitchaiporn, S., Sirisriro, R. & Rajatanavin, R. (2003) Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. Journal of Clinical Endocrinology and Metabolism, 88, 3966-3972.
25. Mangiagli, A., De Sanctis, V., Campisi, S., Di Silvestro, G. & Urso, L. (2000) Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine. Journal of Pediatric Endocrinology and Metabolism, 13, 677-680.
26. Marx, R.E., Sawatari, Y., Fortin, M. & Broumand, V. (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of Oral and Maxillofacial Surgery, 63, 1567-1575.
27. Morabito, N., Lasco, A., Gaudio, A., Crisafulli, A., Di Pietro, C., Meo, A. & Frisina, N. (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporosis International, 13, 644-649.
28. Odvina, C.V. (2006) Osteoporosis: how should it be treated? Journal of Investigative Medicine, 54, 114-122.
29. Perrotta, S., Cappellini, M.D., Bertoldo, F., Servedio, V., Iolascon, G., D'Agruma, L., Gasparini, P., Siciliani, M.C. & Iolascon, A. (2000) Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. British Journal of Haematology, 111, 461-466.
30. Porter, J.B. & Davis, B.A. (2002) Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Practice & Research. Clinical Haematology, 15, 329-368.
31. Recker, R.R., Kimmel, D.B., Parfitt, A.M., Davies, K.M., Keshawarz, N. & Hinders, S. (1988) Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. Journal of Bone and Mineral Research, 3, 133-144.
32. Reid, I.R., Cundy, T., Ibbertson, H.K. & King, A.R. (1993) Osteomalacia after pamidronate for Paget's disease. Lancet, 342, 1459-1460.
33. Shane, E. (2010) Evolving data about subtrochanteric fractures and bisphosphonates. New England Journal of Medicine, 362, 1825-1827.
34. Terpos, E. & Voskaridou, E. (2010) Treatment options for thalassemia patients with osteoporosis. Annals of the New York Academy of Sciences, 1202, 237-243.
35. Vogiatzi, M.G., Tsay, J., Verdelis, K., Rivella, S., Grady, R.W., Doty, S., Giardina, P.J. & Boskey, A.L. (2010) Changes in bone microarchitecture and biomechanical properties in the th3 thalassemia mouse are associated with decreased bone turnover and occur during the period of bone accrual. Calcified Tissue International, 86, 484-494.
36. Voskaridou, E., Terpos, E., Spina, G., Palermos, J., Rahemtulla, A., Loutradi, A. & Loukopoulos, D. (2003) Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. British Journal of Haematology, 123, 730-737.
37. Voskaridou, E., Christoulas, D., Christoulas, E. & Terpos, E. (2008) Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis. Acta Haematologica, 119, 40-44.
38. Weatherall, D.J. (1998) Pathophysiology of thalassaemia. Baillieres Clinical Haematology, 11, 127-146.
39. Whyte, M.P., Wenkert, D., Clements, K.L., McAlister, W.H. & Mumm, S. (2003) Bisphosphonate-induced osteopetrosis. New England Journal of Medicine, 349, 457-463.
40. Wonke, B., Jensen, C., Hanslip, J.J., Prescott, E., Lalloz, M., Layton, M., Erten, S., Tuck, S., Agnew, J.E., Raja, K., Davies, K. & Hoffbrand, A.V. (1998) Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. Journal of Pediatric Endocrinology and Metabolism, 11, 795-801.
41. Wysowski, D.K. (2010) Oral bisphosphonates and oesophageal cancer. BMJ, 341, c4506.